

ASX Release

Overview of David Phillips

PERTH, AUSTRALIA – 20 May 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, further to our announcement of the 17th May, provides further information on Mr. David Phillips' background and experience.

David has spent over 30 years in the global healthcare industry including 14 years in sales and marketing with Glaxo Wellcome, then with Cephalon Inc, Oxford Molecular Group Plc, and latterly eight years with SR One (GSK's Corporate Venture Fund).

In between the two periods with GSK, David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC (prior to the divestment to Galapagos NV where he stayed with the business). David re-joined GlaxoSmithKline's (GSK) SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early stage life science companies.

He has divested a number of R&D operations and drug delivery technologies and he led the team that divested GSK's opiates business in Australia in 2015. David has been a senior investment manager at BioScience Managers Pty Ltd, a leading life sciences investment firm, headquartered in Melbourne.

David is based in Melbourne and is looking to assist SUDA to further expand the business development for all of SUDA's project range throughout the Asia-Pacific region as well as looking for new co-development opportunities globally.

David is engaged under a consultancy service agreement with SUDA. The key terms of David's service agreement:

- Termination date: 30th June 2020
- Remuneration \$10,000 per month.
- Notice period for termination one month.



Further information:

Stephen Carter

Managing Director and Chief Executive Officer

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:**About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety and cancer. For more information, visit www.sudapharma.com